TIRZEPATIDE (Mounjaro®)

Clinical Indication

For treating type 2 diabetes

Comments

Once weekly preparation available only in line with NICE NG28

Not to be used alongside DPP-4 inhibitors

First choice GLP-1 RA for T2DM new starts where BMI < 35 – SC semaglutide (Ozempic)

First choice GLP-1 RA for T2DM new starts where BMI > 35 – SC semaglutide (Ozempic) or SC tirzepatide (Mounjaro)

Date of classification

December 2023

Yellow

Specialist recommendation: Medicines initiated (and stabilised where appropriate) or recommended by a specialist service for prescribing in primary care. Requests should be clearly communicated either through written communication including using approved paperwork if available or verbal means as appropriate .